Latest Headlines

Latest Headlines

SynapDx and the Broad Institute link to use next-gen sequencing for better autism tests

Startup SynapDx will team with the famed Broad Institute of Harvard and MIT to advance next-generation DNA sequencing for more accurate and clinically useful autism diagnostic tools.

Sage snags $38M from A-list VCs to bankroll its seizure drugs

Cambridge, MA's Sage Therapeutics has hauled in a $38 million Series C, convincing a who's-who of biotech investors to pitch in as it pushes forward with a portfolio of central nervous system treatments.

UPDATED: Third Rock backs $14M round for Igenica's cancer-fighting antibodies

The antibody upstart Igenica has rounded up $14 million in venture cash to move its lead drug into the clinic. The Column Group, 5AM Ventures, OrbiMed and Third Rock Ventures all participated in the round.

Amazon's Jeff Bezos bets some of his personal cash on Juno's immunotherapy tech

Amazon founder and new media mogul Jeff Bezos is investing a bit of his personal fortune in Seattle-based Juno Therapeutics, a biotech startup that's been making some big waves in the immunotherapy world.

Foundation Medicine shows test's worth as a highly specific blood cancer screening tool

Foundation Medicine is touting some promising new data highlighting the utility of its signature diagnostic technology for blood cancers, news that will help the newly public Massachusetts startup maintain development and commercial momentum.

Alzheimer's experts team up with Adimab, grab $10M to launch Alector

A pair of scientifists with deep roots in the Alzheimer's field is partnering up with two high-profile antibody development experts with a well-developed platform technology to launch a new biotech with ambitious plans to build a pipeline of new medications to combat the memory-wasting disease. And they're getting $10 million in seed cash from two marquee venture groups to get everything going.

Gene therapy upstart launches with $50M and long-term commercial goals

A group of gene therapy experts with a pivotal-stage therapy that's already posted promising early-stage data is being spun out of The Children's Hospital of Philadelphia. The startup biotech is launching with a $50 million funding commitment.

As VC falters, early-stage biotechs look elsewhere for cash

First-time venture deals in biotech cratered to a 17-year low in the first three quarters of 2013, but that doesn't mean startups are starving. As The Burrill Report points out, despite the VC drought, about a quarter of all equity deals in that period went into Series A rounds, meaning early-stage companies are getting creative and nailing down alternative funding sources.

MedImmune leads $12.5M round for new drug aimed at big chemo market

G1 Therapeutics, which was initially seeded by Hatteras Venture Partners to the tune of $600,000, says that the new funds will finance its IND work and point the company to proof-of-concept data on a drug designed to protect against myelosuppression--the loss of blood cells--during chemo. Hatteras Venture Partners and Mountain Group Capital contributed to the round.

JDRF, PureTech launch diabetes startup initiative

The nonprofit diabetes research organization JDRF has teamed up with Boston-based technology development company PureTech to launch a startup creator aimed at speeding the development of new therapies for Type 1 diabetes.